Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Pathway Would Disappear If ACA Repealed, Gottlieb Says

Mar 29 2019

• By Derrick Gingery

US Capitol building at night

Related Content

Pending Biosimilars

Feb 13 2017

Long-Term Opioid Efficacy Studies Will Take Years, Gottlieb Says

Mar 01 2019

Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase

Mar 18 2019

Trump FY 2020 Budget Renews Push To Reform 180-Day Exclusivity

Mar 12 2019

Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal

Mar 15 2019

Gottlieb's Greatest Strength As US FDA Commissioner? Stability

Mar 28 2019

Generic Industry Market Forces May Impact GDUFA III Talks

Mar 22 2019

US FDA Wants Authority To Mandate Minor Post-Approval Quality Changes

Mar 27 2019

Related Companies

Pfizer Inc.

Roche Holding AG

Additional Topics

United States Biosimilars FDA Regulation Legislation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window